Zentiva will include the leuprorelin implant to its portfolio for selected markets in Western Europe. This implant is another successful product of AMW, developed and produced by AMW The leuprorelin implant for the treatment of prostate cancer received its first marketing authorisation in Germany in 2018 and gained market share quickly.
Nick Haggar, CEO of Zentiva: “By partnering with AMW we are getting closer to our goal of serving people in Europe and beyond with high-quality and affordable medicines, especially in the area of oncology. “
Philipp Karbach, Managing Director of AMW: “We are delighted to be one of the strategically relevant partners to enter the market. We have had a good relationship with Zentiva at all levels for many years AMW will continue to increase its market share with Zentiva through Leuprorelin”
Zentiva is a producer of high-quality affordable medicines serving patients in Europe and beyond. With a dedicated team of more than 4,500 people and a network of production sites – including flagship sites in Prague and Bucharest – Zentiva strives to be the champion of branded generic medicines and OTC products in Europe to better support people’s daily healthcare needs. At Zentiva it is our aspiration that healthcare should be a right and not a privilege. More than ever, people need better access to high-quality affordable medicines and healthcare. We work in partnership with physicians, pharmacists, wholesalers, regulators, and governments to provide the everyday solutions that we all depend on.
AMW GmbH is a specialty pharmaceutical company focused on innovative drug delivery systems. Products developed by AMW enable the administration of drugs via implants (subcutaneous) or patches (transdermal) or rings (vaginal). The company was founded in 2008 and develops therapeutic solutions in oncology, neurology, dermatology, pain management, and ophthalmology.
AMW is based in Warngau, south of Munich.